(Investor’s Business Daily) – Medicine: After the recess appointment of a Medicare and Medicaid head, an FDA panel drops its endorsement of a widely used cancer drug. Another FDA-approved cancer therapy may not be paid for. It begins.
It didn’t take long for the health care philosophy of Dr. Donald Berwick, President Obama’s choice to head the Centers for Medicaid and Medicare Services, and an appointee we have labeled a “one-man death panel,” to have an effect.
Berwick is an admirer of Britain’s National Health Service and its National Institute for Clinical Excellence, with the Orwellian-acronym NICE.
“NICE,” Berwick has said, “is extremely effective and a conscientious, valuable and